Bruker’s BRKR strong growth reflects its fundamental commitment to innovate high-value solutions and ongoing portfolio transformation. Yet, the company’s operations face the wrath of excessive ...

This milestone marks a significant step forward in Rakovina’s mission to accelerate drug discovery using advanced AI-driven platforms. In September 2024, Rakovina announced its partnership with ...

In its fourth quarter 2024 investor letter, The London Company SMID Cap Strategy emphasized stocks such as Bruker Corporation (NASDAQ:BRKR). Bruker Corporation (NASDAQ:BRKR) focuses on developing ...

Figure 1. Simultaneous multimodal imaging (height, adhesion, and IR absorption) enabled by REFV AFM-IR. Image Credit: Bruker Nano Surfaces and Metrology REFV AFM-IR offers its users: The ability to ...

Table 1. Similarities and differences between ATR-FTIR and XRPD in the analysis of suspected samples. 2 Usefulness and potential of the infrared (IR) technique in pharmaceutical analysis. 2.1 Basic ...

The HYPERION II is Bruker's versatile FT-IR microscope for research and development with flexible accessories and the possibility to combine Infrared Laser Imaging (QCL) and FT-IR in one instrument.

Bruker (BRKR) reported $979.6 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 14.6%. EPS of $0.76 for the same period compares to $0.70 a year ago.

BRUKER ($BRKR) posted quarterly earnings results on Thursday, February 13th. The company reported earnings of $0.76 per share, beating estimates of $0.75 by $0.01 ...

(3) Bruker Scientific Instruments (BSI) revenue reflects the sum of the BSI BioSpin, CALID and Nano Segments as presented in our Annual Report on Form 10-K for the year ended December 31 ...